Form 4 for OFIX Orthofix Medical Inc.
Accepted 2023-10-17 00:00:00 ET · period of report 2023-10-15 · accession 0001209191-23-052978 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-10-17 | 2023-10-15 | OFIX | BURZIK CATHERINE M | Interim CEO, Dir | A - Grant | $0.00 | +120.7K | 158.6K | +318% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-15 | A | A | 120,676 | $0.00 | 158,625 | D | — | — | (F1) The restricted stock units vest in full ninety (90) calendar days following the date that a successor Chief Executive Officer of Issuer assumes office following the Reporting Person's discontinuation of service as Interim Chief Executive Officer of Issuer. (F2) Includes 32,763 previously reported deferred stock units. |